Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation

• Status: Terminated
• Trial end date: 2021-04-13
• Target enrollment: 0
• Participant gender: All

Summary

Condorde main objective is to evaluate the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed on ctDNA after liquid biopsy. EGFR status will be assessed by real time PCR (rtPCR), digital PCR (dPCR) and Next Generation Sequencing (NGS) in patients with chemotherapy naive lung carcinoma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Oscar Lambret
• Collaborator: University Hospital, Lille

Criteria

Inclusion Criteria:

• At least 18 years

• Metastatic lung carcinoma

• With: - EGFR gene mutation

• Or at least 2 predictive factors of addictive mutation (Women, non smocking or cessation > 3 years, Asiatic, lung adenocarcinoma)

• Eligible for 1st line treatment

• Performance status ≤ 3

• Available tumor sample or tumor reachable for biopsy

• With informed and signed consent

• Affiliation to the National Social Security System

Exclusion Criteria:

• Previous radiotherapy treatment in months preceding initials samples

• Pregnant or breastfeeding women

• Patient not able to give consent or unwilling to provide consent